{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:04:33Z","timestamp":1794539073092,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boerhinger Ingelheim"},{"name":"GSK and Novartis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Difficult-to-treat RA (D2T RA) is an area of high unmet need. The prevalence reported in the first D2T RA cohort studies ranged from 5.5% to 27.5%. Key to the definition is a conviction by the patient and\/or rheumatologist that disease management has become problematic and failure of at least two biological or targeted synthetic DMARDs. D2T RA is a multifactorial disease state which was reflected in data from D2T RA cohort studies: these pointed towards high prevalence of comorbidities and\/or lower socioeconomic status in D2T RA subgroups, while others had persistent symptoms without these factors being present. A holistic approach is necessary to identify the root problems underlying D2T RA in individual patients. In this review, biological and non-biological drivers that should be considered to be optimized will be discussed in view of what we have learned from patient data emerging from the first D2T RA cohort studies.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae544","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:20:06Z","timestamp":1728505206000},"page":"65-73","source":"Crossref","is-referenced-by-count":66,"title":["Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?"],"prefix":"10.1093","volume":"64","author":[{"given":"Zonne L M","family":"Hofman","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia M T","family":"Roodenrijs","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]},{"name":"Rheumatology Department, King\u2019s College Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison L","family":"Kent","sequence":"additional","affiliation":[{"name":"EULAR PARE Community , Z\u00fcrich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University , Budapest,","place":["Hungary"]},{"name":"Heart and Vascular Center, Semmelweis University , Budapest,","place":["Hungary"]},{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University , Budapest,","place":["Hungary"]},{"name":"National Institute of Locomotor Diseases and Disabilities , Budapest,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-5785","authenticated-orcid":false,"given":"Jaap M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2025010608385160700_keae544-B1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2025010608385160700_keae544-B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B3","first-page":"17","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nature reviews","volume":"17","author":"Buch","year":"2021","journal-title":"Rheumatology"},{"key":"2025010608385160700_keae544-B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B5","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","article-title":"Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search","volume":"61","author":"Roodenrijs","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B7","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"key":"2025010608385160700_keae544-B8","doi-asserted-by":"crossref","first-page":"e0289760","DOI":"10.1371\/journal.pone.0289760","article-title":"Refractory inflammatory arthritis definition and model generated through patient and multi-disciplinary professional modified delphi process","volume":"18","author":"Chaplin","year":"2023","journal-title":"PloS one"},{"key":"2025010608385160700_keae544-B9","doi-asserted-by":"crossref","first-page":"SI235","DOI":"10.1093\/rheumatology\/kead487","article-title":"Comorbidities in RA: bringing them to the limelight","volume":"62","author":"Nikiphorou","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B10","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","article-title":"Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?","volume":"62","author":"Dey","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B11","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.mayocp.2019.08.010","article-title":"Comorbidities as risk factors for rheumatoid arthritis and their accrual after diagnosis","volume":"94","author":"Kronzer","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2025010608385160700_keae544-B12","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/rheumatology\/keaa841","article-title":"Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial","volume":"60","author":"Stouten","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B13","doi-asserted-by":"publisher","first-page":"e2119400","DOI":"10.1001\/jamanetworkopen.2021.19400","article-title":"Socioeconomic disparities in functional status in a national sample of patients with rheumatoid arthritis","volume":"4","author":"Izadi","year":"2021","journal-title":"JAMA Net Open"},{"key":"2025010608385160700_keae544-B14","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/keab598","article-title":"Predictors of poor function in RA based on two prospective UK inception cohorts. do comorbidities matter?","volume":"61","author":"Busby","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","article-title":"Mechanisms for joint pain in rheumatoid arthritis (RA): from cytokines to central sensitization","volume":"16","author":"Zhang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"2025010608385160700_keae544-B16","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/S2665-9913(23)00007-3","article-title":"Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics","volume":"5","author":"Stefanov","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025010608385160700_keae544-B17","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/art.41440","article-title":"Association of dysregulated central pain processing and response to Disease\u2013Modifying antirheumatic drug therapy in rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis & rheumatology (Hoboken, N.J"},{"key":"2025010608385160700_keae544-B18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40001-023-01224-1","article-title":"Enhanced activity of the left precuneus as a predictor of visuospatial dysfunction correlates with disease activity in rheumatoid arthritis","volume":"28","author":"Zheng","year":"2023","journal-title":"Eur J Med Res"},{"key":"2025010608385160700_keae544-B19","first-page":"8342","article-title":"Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis","volume":"33","author":"Sakiyama","year":"2023","journal-title":"Cereb Cortex (New York, N.Y. 1991"},{"key":"2025010608385160700_keae544-B20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/art.42755","volume":"76","author":"Dehsarvi","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025010608385160700_keae544-B21","doi-asserted-by":"publisher","first-page":"e001512","DOI":"10.1136\/rmdopen-2020-001512","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"Rheumatic & musculoskeletal diseases open"},{"key":"2025010608385160700_keae544-B22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature (London"},{"key":"2025010608385160700_keae544-B23","first-page":"356","article-title":"Associations between rheumatoid arthritis clinical factors with synovial cell types and states","volume":"76","author":"Weisenfeld","year":"2023","journal-title":"Arth Rheumatol (Hoboken, N.J.)"},{"key":"2025010608385160700_keae544-B24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2025010608385160700_keae544-B25","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nature medicine"},{"key":"2025010608385160700_keae544-B26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","article-title":"A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front Immunol"},{"key":"2025010608385160700_keae544-B27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature (London"},{"key":"2025010608385160700_keae544-B28","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1093\/rheumatology\/keab078","article-title":"Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study","volume":"60","author":"Roodenrijs","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B29","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1093\/rheumatology\/keab130","article-title":"Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study","volume":"60","author":"Roodenrijs","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B30","doi-asserted-by":"publisher","first-page":"e001511","DOI":"10.1136\/rmdopen-2020-001511","article-title":"Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"Rheum Musculosk Dis open"},{"key":"2025010608385160700_keae544-B31","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead694","article-title":"Patient\u2013physician discordance impairs outcomes in early rheumatoid arthritis through less consistent treat-to-target implementation","author":"Doumen","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","article-title":"Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study","volume":"62","author":"Giollo","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002842","article-title":"Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease","volume":"9","author":"Leon","year":"2023","journal-title":"RMD Open"},{"key":"2025010608385160700_keae544-B35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00296-023-05349-8","article-title":"Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations","volume":"43","author":"Garcia-Salinas","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025010608385160700_keae544-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthr Res Ther"},{"key":"2025010608385160700_keae544-B37","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00296-022-05124-1","article-title":"Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis","volume":"42","author":"Yoshii","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025010608385160700_keae544-B38","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the british society for rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B40","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B41","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","article-title":"Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease","volume":"60","author":"Roodenrijs","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B42","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a french single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","article-title":"Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort","volume":"45","author":"Watanabe","year":"2022","journal-title":"Immunological medicine"},{"key":"2025010608385160700_keae544-B44","first-page":"1114","article-title":"A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification","volume":"41","author":"Novella-Navarro","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025010608385160700_keae544-B45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025010608385160700_keae544-B46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.55563\/clinexprheumatol\/g33ia5","article-title":"Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic\/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry","volume":"40","author":"Ochi","year":"2022","journal-title":"Clinical and Experimental Rheumatology"},{"key":"2025010608385160700_keae544-B47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/rheumatology\/keac213","article-title":"New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis","volume":"62","author":"Pazmino","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025010608385160700_keae544-B48","doi-asserted-by":"crossref","first-page":"e003382","DOI":"10.1136\/rmdopen-2023-003382","article-title":"Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b\/tsDMARD treatment","volume":"9","author":"Novella-Navarro","year":"2023","journal-title":"RMD Open"},{"key":"2025010608385160700_keae544-B49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arth Res Ther"},{"key":"2025010608385160700_keae544-B50","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae544\/60298175\/keae544.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/65\/60298175\/keae544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/65\/60298175\/keae544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:39:58Z","timestamp":1736152798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/1\/65\/7816327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,9]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae544","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,9]]}}}